Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02262637
NCT02262637CompletedNot Applicable

Micardis® / MicardisPlus® PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)

Boehringer Ingelheim0 sites4,814 target enrollmentStarted: September 2003Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
4,814
Primary Endpoint
Change in systolic blood pressure (SBP)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age >= 18 years

Exclusion Criteria

  • •Age < 18 years

Arms & Interventions

Hypertensive patients - Nephrologists

Intervention: Micardis® (Drug)

Hypertensive patients - Cardiologists

Intervention: MicardisPlus® (Drug)

Hypertensive patients - Diabetologists

Intervention: MicardisPlus® (Drug)

Hypertensive patients - Nephrologists

Intervention: MicardisPlus® (Drug)

Hypertensive patients - Diabetologists

Intervention: Micardis® (Drug)

Hypertensive patients - Cardiologists

Intervention: Micardis® (Drug)

Outcomes

Primary Outcomes

Change in systolic blood pressure (SBP)

Time Frame: baseline, up to 6 months

Change in diastolic blood pressure (DBP)

Time Frame: baseline, up to 6 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Not Applicable
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With HypertensionHypertension
NCT02242357Boehringer Ingelheim14,553
Completed
Not Applicable
Post-Marketing Surveillance Study of Micardis® Plus in Patients With HypertensionHypertension
NCT02238275Boehringer Ingelheim8,135
Completed
Not Applicable
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential HypertensionHypertension
NCT02176850Boehringer Ingelheim19,870
Completed
Not Applicable
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood PressureHypertension
NCT02242864Boehringer Ingelheim1,527
Completed
Not Applicable
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes MellitusHypertension
NCT02242825Boehringer Ingelheim8,148